Trials / Recruiting
RecruitingNCT04161664
Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy
Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy (CRAVAT)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- The Netherlands Cancer Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neo adjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive thereby diminishing the chance for morbidity.
Detailed description
Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neo adjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive thereby diminishing the chance for morbidity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel and Carboplatin | 6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule |
Timeline
- Start date
- 2020-01-16
- Primary completion
- 2024-01-01
- Completion
- 2029-01-01
- First posted
- 2019-11-13
- Last updated
- 2022-10-19
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04161664. Inclusion in this directory is not an endorsement.